Last reviewed · How we verify
Prasugel
Prasugel, developed by Chonnam National University Hospital, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the credibility of its academic institution origin. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Prasugel |
|---|---|
| Sponsor | Chonnam National University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study (PHASE4)
- Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prasugel CI brief — competitive landscape report
- Prasugel updates RSS · CI watch RSS
- Chonnam National University Hospital portfolio CI